Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-Le Initiated first ...

Launched Niktimvo in the U.S. in late January, in partnership with Incyte. Niktimvo is approved by the U.S. FDA for the treatment of chronic graft-versus-host disease (GVHD) after failure of at least ...

New York State Common Retirement Fund boosted its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Free Report) by 13.5% in the fourth quarter, Holdings Channel reports. The fund owned ...

Analysts at B. Riley raised their Q1 2025 earnings per share estimates for Madrigal Pharmaceuticals in a research report issued on Thursday, February 27th. B. Riley analyst M. Mamtani now expects that ...

AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...

The BioWorld Biopharmaceutical Index (BBI) ended 2024 down 2.24%, despite hitting a peak of 25.19% in late August. While it ...

Cambridge-based Draper Labs is set to launch their NASA-funded CP-12 mission in 2026, racing Texas-based Firefly Aerospace to ...

The Novato-based maker of biopharmaceutical treatments for rare diseases plans to release this year a new gene therapy for ...

In contrast to drugs like cocaine or marijuana, psychedelics are strong and give users access to a kind of "alternate reality ...

Feb. 25, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced the expansion of its Board of Directors with the appointments of Teri ...

We recently compiled a list of the 12 Best Psychedelic Stocks to Buy in 2025. In this article, we are going to take a look at ...

This week's issue of Rubber News features our special report on the energy, oil and gas industries, including a deeper look ...